Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 3Active not recruiting 2Terminated 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Breast Neoplasms 2Kidney Neoplasms 1Hereditary Breast and Ovarian Cancer Syndrome 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Breast Carcinoma In Situ 1

Interventions

pembrolizumab 1262Specimen Handling 924Magnetic Resonance Spectroscopy 829Carboplatin 821Cyclophosphamide 799Cisplatin 722Nivolumab 667Paclitaxel 627Radiotherapy 608Gemcitabine 570Biopsy 557Bevacizumab 478Dexamethasone 437fludarabine 407Docetaxel 377venetoclax 367Oxaliplatin 364Capecitabine 355Fluorouracil 355atezolizumab 350durvalumab 332Rituximab 329Drug Therapy 325Doxorubicin 316Radiosurgery 314Standard of Care 309Blood Specimen Collection 308Pemetrexed 304Ipilimumab 298Radiation 285

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Genotype × 1 year × Clear all
NCT05006196 2026-05-20

IMOGEN

Perspectum

Active not recruiting
1,030 enrolled
Breast

Breast Diseases, Breast Neoplasms

NCT05755269 2026-05-01

Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women

Mayo Clinic

Terminated
19 enrolled
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating

NCT07432308 2026-03-06

Liquid biopsy

Institute of Oncology Ljubljana

Phase NA Completed
22 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02404584 2025-12-04

GenCInibs-Suni

Centre Hospitalier Universitaire de Nīmes

Completed
43 enrolled
Genitourinary

Kidney Neoplasms

NCT05120284 2025-08-29

Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)

University of Florida

Phase 2 Active not recruiting
40 enrolled
CNS

Glioblastoma

NCT06534424 2025-06-27

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

Ohio State University Comprehensive Cancer Center

Phase NA Completed
152 enrolled
BreastGynecologic

Hereditary Breast and Ovarian Cancer Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡